Sheets Smith Wealth Management grew its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 1.9% during the fourth quarter, HoldingsChannel reports. The firm owned 54,700 shares of the medical research company’s stock after acquiring an additional 1,000 shares during the quarter. Iqvia makes up approximately 1.7% of Sheets Smith Wealth Management’s portfolio, making the stock its 7th biggest holding. Sheets Smith Wealth Management’s holdings in Iqvia were worth $6,354,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Barings LLC increased its holdings in Iqvia by 74.1% in the third quarter. Barings LLC now owns 18,962 shares of the medical research company’s stock valued at $2,460,000 after buying an additional 8,070 shares during the last quarter. State Treasurer State of Michigan increased its holdings in Iqvia by 1.0% in the third quarter. State Treasurer State of Michigan now owns 48,300 shares of the medical research company’s stock valued at $6,266,000 after buying an additional 500 shares during the last quarter. BP PLC increased its holdings in Iqvia by 5.0% in the third quarter. BP PLC now owns 21,000 shares of the medical research company’s stock valued at $2,725,000 after buying an additional 1,000 shares during the last quarter. Northern Trust Corp increased its holdings in Iqvia by 7.0% in the second quarter. Northern Trust Corp now owns 1,877,470 shares of the medical research company’s stock valued at $187,408,000 after buying an additional 122,260 shares during the last quarter. Finally, Oliver Luxxe Assets LLC purchased a new position in Iqvia in the third quarter valued at $739,000. Institutional investors own 90.13% of the company’s stock.

In other news, major shareholder Canada Pension Plan Investment sold 3,164,388 shares of the stock in a transaction dated Tuesday, December 4th. The shares were sold at an average price of $123.72, for a total transaction of $391,498,083.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael R. Mcdonnell sold 9,500 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $128.35, for a total transaction of $1,219,325.00. The disclosure for this sale can be found here. Insiders have sold 6,747,433 shares of company stock valued at $834,836,396 in the last quarter. Insiders own 6.00% of the company’s stock.

Shares of IQV stock traded down $1.84 during mid-day trading on Friday, hitting $121.52. 19,321 shares of the stock were exchanged, compared to its average volume of 1,357,992. The firm has a market cap of $24.44 billion, a price-to-earnings ratio of 27.87, a PEG ratio of 1.55 and a beta of 0.81. Iqvia Holdings Inc has a 12-month low of $91.57 and a 12-month high of $135.48. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.03. The company had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.58 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The business’s revenue was up 5.2% on a year-over-year basis. As a group, research analysts predict that Iqvia Holdings Inc will post 5.13 EPS for the current year.

IQV has been the topic of several recent analyst reports. Goldman Sachs Group raised Iqvia from a “buy” rating to a “conviction-buy” rating in a report on Friday. Robert W. Baird increased their target price on Iqvia from $143.00 to $146.00 and gave the company an “outperform” rating in a report on Tuesday, October 2nd. UBS Group initiated coverage on Iqvia in a report on Tuesday, October 9th. They issued a “buy” rating on the stock. Royal Bank of Canada increased their target price on Iqvia to $137.00 and gave the company an “outperform” rating in a report on Tuesday, October 23rd. Finally, Barclays increased their target price on Iqvia from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, October 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $135.81.

COPYRIGHT VIOLATION WARNING: “Sheets Smith Wealth Management Grows Holdings in Iqvia Holdings Inc (IQV)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2019/01/11/sheets-smith-wealth-management-grows-holdings-in-iqvia-holdings-inc-iqv.html.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Read More: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.